Objective:Detection of Activating Transcription Factor-2 (ATF-2) expression in Diffuse Large B-cell Lymphoma (DLBCL) and its relationship with clinicopathological significance.Method:Pathological diagnosis and clinica...Objective:Detection of Activating Transcription Factor-2 (ATF-2) expression in Diffuse Large B-cell Lymphoma (DLBCL) and its relationship with clinicopathological significance.Method:Pathological diagnosis and clinical data were collected in DLBCL. Immunohistochemical (IHC) was applied for ATF-2 expression in DLBCL.Result: Positive rate of ATF2 expression in DLBCL was 81% (64/79). We found ATF2 expression was not related to gender, age, clinical staging, immunological phenotype, and EBV infection, Ki-67, CyclinD1 and Bcl-2. The positive rate of both ATF-2, Bcl-6 was 62.0% (49/79), ATF-2 was associated with Bcl-6;the higher expression of ATF-2 is correlated with the poor survival time in DLBCL.Conclusion: High expression of ATF-2 expression is associated with poor prognosis in DLBDL, suggesting that ATF-2 may be an independent prognostic factor for diffuse large B cell lymphoma.展开更多
文摘Objective:Detection of Activating Transcription Factor-2 (ATF-2) expression in Diffuse Large B-cell Lymphoma (DLBCL) and its relationship with clinicopathological significance.Method:Pathological diagnosis and clinical data were collected in DLBCL. Immunohistochemical (IHC) was applied for ATF-2 expression in DLBCL.Result: Positive rate of ATF2 expression in DLBCL was 81% (64/79). We found ATF2 expression was not related to gender, age, clinical staging, immunological phenotype, and EBV infection, Ki-67, CyclinD1 and Bcl-2. The positive rate of both ATF-2, Bcl-6 was 62.0% (49/79), ATF-2 was associated with Bcl-6;the higher expression of ATF-2 is correlated with the poor survival time in DLBCL.Conclusion: High expression of ATF-2 expression is associated with poor prognosis in DLBDL, suggesting that ATF-2 may be an independent prognostic factor for diffuse large B cell lymphoma.
